ReleaseWire Connect

Partnership Delivers Synergy of Infrastructural Resources for Clinical Development and Bioprocessing Technologies in Cellular Therapy

Avalon's CAR-Ts are ahead of their time due to key advantages over conventional medicines. AVA-101 shuttles enough genes to decimate two oncology targets (CD19 and CD22).

Investor News Source takes a look into the recent insider buying of Avalon GloboCare (NASDAQ:AVCO)

Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of cell-based technologies and therapeutics and is poised to take advantage of the Chinese trade deal optimism from recents weeks. Based on the recent positive material events, the company is requesting coverage from media outlets. Please review the recent positive events below and contact the company or the issuer of this release to initiate coverage.

Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of cell-based technologies and therapeutics, is poised to take advantage of the Chinese trade deal optimism from last week. Avalon Globocare closed the week on Nov 7th just over even on the week however there was an increase in liquidity from the week before and 3/5 trading sessions closed a green signaling regimen investor optimism.

Rapid Nutrition PLC (OTCQB:RPNRF) ("Company"), a natural healthcare company focused on the research, development and production of a range of life science products, today announced that it intends to apply for submission to trade on the OTCQX® Best Market.

Being healthy is one the key factors in living a long and happy life. The saying goes that "health is wealth," which is absolutely true because the more someone is unhealthy, then they will be subject to higher insurance premiums, greater healthcare costs, downgraded life expectancy, and more. Without maintaining a keen eye on your health, it will certainly cost you more than money over the long term.

Avalon GloboCare Corp. (NASDAQ:AVCO), a leading clinical-stage global developer of cell-based technologies and therapeutics, announced that they have established a strategic partnership with GE Healthcare. The partnership will accelerate Avalon's standardization, automation and bio-production for clinical-grade Chimeric Antigen Receptor (CAR)-T cells and other immune-effector cells for cellular immunotherapy, as well as exosomes/extracellular vesicles (EV) based regenerative therapeutics. The combination of expertise sets the stage for Avalon to be the leader in cellular medicines with the ability to execute on the complete development lifecycle from innovation through bio-production to the delivery and management of treatment at hospitals for patients. This infrastructure and depth of capabilities ensures the successful execution of the company's ongoing clinical trials.

Avalon GloboCare Corp. (NASDAQ:AVCO) announced a strategic partnership with GE Healthcare (NYSE:GE) on July 22. The deal is designed to accelerate Avalon's standardization, automation and bio-production for CAR-T cells and other cellular therapies related to immunotherapy. This includes exosomes/extracellular vesicles (EV)-based regenerative therapeutics.

Avalon GloboCare Corp. (NASDAQ:AVCO), a leading clinical-stage global developer of cell-based technologies and therapeutics, today announced that they have established a strategic partnership with GE Healthcare (NYSE:GE) . The partnership will accelerate Avalon's standardization, automation and bio-production for clinical-grade Chimeric Antigen Receptor (CAR)-T cells and other immune-effector cells for cellular immunotherapy, as well as exosomes/extracellular vesicles (EV) based regenerative therapeutics. The combination of expertise sets the stage for Avalon to be the leader in cellular medicines with the ability to execute on the complete development lifecycle from innovation through bio-production to the delivery and management of treatment at hospitals for patients. This infrastructure and depth of capabilities ensures the successful execution of the company's ongoing clinical trials.